142 related articles for article (PubMed ID: 36856777)
1. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
4. Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone.
Layfield LJ; Frazier S; Esebua M; Schmidt RL
Pathol Res Pract; 2016 Mar; 212(3):190-5. PubMed ID: 26839158
[TBL] [Abstract][Full Text] [Related]
5. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
6. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
[TBL] [Abstract][Full Text] [Related]
7. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
Hum Pathol; 2024 May; 148():51-59. PubMed ID: 38740270
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.
Tsuda H; Sasano H; Akiyama F; Kurosumi M; Hasegawa T; Osamura RY; Sakamoto G
Pathol Int; 2002 Feb; 52(2):126-34. PubMed ID: 11940217
[TBL] [Abstract][Full Text] [Related]
10. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
van der Vegt B; de Bock GH; Bart J; Zwartjes NG; Wesseling J
Mod Pathol; 2009 Jul; 22(7):879-86. PubMed ID: 19305385
[TBL] [Abstract][Full Text] [Related]
11. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
[TBL] [Abstract][Full Text] [Related]
12. [Intralaboratory reproducibility of HER2 testing in breast cancer by immunohistochemistry and comparison of results obtained by different assays].
Yang Y; Wei B; Zhang Z; Tang Y; Fu J; Liao DY; Li FY; Bu H
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):29-34. PubMed ID: 19489222
[TBL] [Abstract][Full Text] [Related]
13. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
14. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
[TBL] [Abstract][Full Text] [Related]
15. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH).
Mayr D; Heim S; Werhan C; Zeindl-Eberhart E; Kirchner T
Virchows Arch; 2009 Mar; 454(3):241-8. PubMed ID: 19169706
[TBL] [Abstract][Full Text] [Related]
18. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver
Miladinović M; Vučković L; Klisic A
Open Med (Wars); 2021; 16(1):1503-1512. PubMed ID: 34708154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]